Growth Hormone Secretagogues
Hexarelin
A synthetic growth hormone-releasing hexapeptide studied in small human endocrine-response experiments; it has no FDA-approved indication.
- Investigational
- Ghrelin Receptor
- Human Studies
- WADA Prohibited
Research register / 2026
CJC-1295 and the growth-hormone release axis.
An evidence-focused English reference on CJC-1295 and growth hormone-releasing peptides, including Ipamorelin, Sermorelin and GHRP-6.
- Evidence notes
- 212
- Compound files
- 6
- Editorial desks shown
- 3
Two receptor routes. Four separate conclusions.
GHRH receptor
CJC-1295 and Sermorelin belong to the GHRH-analogue side of the index.
Ghrelin receptor
Ipamorelin and GHRP-6 are catalogued as growth-hormone secretagogues.
- 01GH or IGF-1 biomarkers
- 02Body-composition outcomes
- 03Disease outcomes
- 04FDA approval status
Compound dossiers
View full indexGHRH Analogues
CJC-1295 no DAC / Modified GRF (1-29)
A short-acting modified GHRH (1-29) analogue commonly marketed as CJC-1295 no DAC; distinct from albumin-binding CJC-1295 with DAC.
- Investigational
- GHRH Analogue
- WADA Prohibited
Growth Hormone Secretagogues
GHRP-6
- Investigational
- Ghrelin Receptor
- Human Studies
- WADA Prohibited
Recent evidence notes
View all 212 notes2026-08-072 min
CJC-1295 and Ipamorelin Combination: Evidence Checklist and Evidence Boundaries
An evidence-led CJC-1295 and Ipamorelin Combination review focused on evidence checklist, human-study limits, regulatory context and claim verification.
Reviewed by Regulatory Review Desk2026-08-072 min
CJC-1295 and Ipamorelin Combination: Research Gaps Map and Evidence Boundaries
An evidence-led CJC-1295 and Ipamorelin Combination review focused on research gaps map, human-study limits, regulatory context and claim verification.
Reviewed by Sports Integrity Desk2026-08-072 min
CJC-1295 and Ipamorelin Combination: Glucose and Metabolic Context and Evidence Boundaries
An evidence-led CJC-1295 and Ipamorelin Combination review focused on glucose and metabolic context, human-study limits, regulatory context and claim verification.
Reviewed by Endocrine Evidence Desk2026-08-072 min
CJC-1295 and Ipamorelin Combination: Healthy-Aging Claims and Evidence Boundaries
An evidence-led CJC-1295 and Ipamorelin Combination review focused on healthy-aging claims, human-study limits, regulatory context and claim verification.
Reviewed by Endocrine Evidence Desk2026-08-062 min
CJC-1295 and Ipamorelin Combination: Sleep Claims and Evidence Boundaries
An evidence-led CJC-1295 and Ipamorelin Combination review focused on sleep claims, human-study limits, regulatory context and claim verification.
Reviewed by Endocrine Evidence Desk2026-08-062 min
CJC-1295 and Ipamorelin Combination: Recovery and Injury Claims and Evidence Boundaries
An evidence-led CJC-1295 and Ipamorelin Combination review focused on recovery and injury claims, human-study limits, regulatory context and claim verification.
Reviewed by Regulatory Review DeskSubject index
CJC-129558 notes
Evidence, safety and regulatory analysis of CJC-1295.
Ipamorelin56 notesMechanism, human studies and safety information on Ipamorelin.
Sermorelin30 notesSermorelin evidence, approval history and comparison articles.
GHRP-628 notesGHRP-6 mechanism, metabolic effects and evidence.
Human Studies133 notesArticles centered on human clinical and pharmacology studies.
Endocrine Safety27 notesSafety signals and evidence gaps involving the GH and IGF-1 axis.
FDA Status27 notesApproval, compounding and regulatory status of GH-axis compounds.
Anti-Doping9 notesCurrent anti-doping rules for CJC-1295 and related compounds.